Richard Gilmore
Cardiovascular Disease · Lake Charles, LANPI 1609842814
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $39,185 of the $45,459 with a category attached, or 86.2%. 30 manufacturers reported payments, led by Esperion Therapeutics, Inc. at 54.6% of the total. Reporting peaked in 2021 at $19,549 and has fallen 97.1% since, to $562 in 2023. Among cardiovascular disease clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 282 payments — averaging $161.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Esperion Therapeutics, Inc.$25K
- AstraZeneca$8K
- Pfizer$5K
- E.r. Squibb & Sons, L.L.C.$4K
- Boston Scientific$745
- Novartis$470
- plus $2K from 24 others
Across 39 payments — averaging $2557.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Esperion Therapeutics, Inc.$58K
- Amgen$31K
- Merck$7K
- Abbott$2K
- E.r. Squibb & Sons, L.L.C.$1K
What the payments were for
- Consulting fees$1,0502%
- Speaking & faculty fees$39,18586%
- Food & beverage$5,04311%
- Education$1810%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Esperion Therapeutics, Inc. | 48 | $24,817 |
| AstraZeneca | 23 | $7,548 |
| Pfizer | 18 | $5,373 |
| E.r. Squibb & Sons, L.L.C. | 23 | $4,165 |
| Boston Scientific | 27 | $745 |
| Novartis | 36 | $470 |
| Abbott | 11 | $456 |
| Amarin Pharma, Inc. | 14 | $256 |
| Boehringer Ingelheim | 13 | $201 |
| Merck | 9 | $174 |
| Biosense Webster, Inc. | 5 | $166 |
| Johnson & Johnson | 10 | $155 |
| Sanofi-aventis U.S. LLC | 6 | $108 |
| Amgen | 7 | $99 |
| Heartflow, Inc. | 1 | $94 |
| Shockwave Medical, Inc | 4 | $84 |
| Bayer | 3 | $77 |
| Abiomed | 4 | $73 |
| Actelion Pharmaceuticals US, Inc. | 3 | $66 |
| Medtronic | 1 | $53 |
| Regeneron Healthcare Solutions, Inc. | 4 | $49 |
| Philips North America LLC | 1 | $46 |
| Intuitive Surgical | 1 | $39 |
| United Therapeutics Corporation | 2 | $30 |
| Silk Road Medical, Inc. | 1 | $26 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $25 |
| Cardiovascular Systems Inc. | 2 | $24 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Irhythm Technologies, Inc. | 1 | $13 |
| Gilead | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEXLIZET$24,301
- NEXLETOL$24,301
- ELIQUIS$8,800
- FARXIGA$7,302
- Ensite Cardiac Mapping System$136
- WATCHMAN Access System$127
- ASSURITY$121
- Watchman$120
- Carto 3$105
How this compares
$45,459 in reported general payments places this provider in the 90th percentile of 281 cardiovascular disease providers in Louisiana.
Other cardiovascular disease in Lake Charles
- Corey FosterLake Charles$158K
- John WintertonLake Charles$15K
- Ahmad AwanLake Charles$13K
- Michael TurnerLake Charles$11K
- Keith FerdinandNew Orleans$239K
- Carl LavieNew Orleans$228K
- Imran ChaudryMonroe$202K
- George KaramBaton Rouge$110K
- Harry HawthorneAlexandria$89K
- Mazen IqbalMonroe$82K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.